The impact of acute lymphoblastic leukemia treatment on central nervous system results in Bogota, Colombia

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 9, 2008, Pages 643-650

  Buendia H, Maria Teresa Amparo ^a   Lozano, Juan Manuel ^b   Suarez, Gloria Elena ^c   Saavedra A, Carlos ^d   Guevara, Gonzalo ^e  

^a UNIVERSIDAD DEL ROSARIO   (Colombia)

^b PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^c Instituto de Cancerologia Clinica las Americas   (Colombia)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^e Instituto Nacional de Cancerología   (Colombia)

Author keywords

CNS leukemia; Developing country; Intensive chemotherapy; Pediatric ALL

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FOLINATE CALCIUM; MERCAPTOPURINE; METHOTREXATE; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CHILD; COLOMBIA; CONTROLLED STUDY; CYTOGENETICS; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COLOMBIA; CRANIAL IRRADIATION; CYTOGENETIC ANALYSIS; HUMANS; INFANT; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; RECURRENCE; REMISSION INDUCTION; RISK; SURVIVAL RATE;

EID: 66249140940     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31817e4a7d     Document Type: Article

References (41)

1. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukemia-current status and future perspectives. Lancet Oncol. 2001;2:597-607.
2. Schrappe M, Reiter A, Ludwig W-D, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthacyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000;95:3310-3322.
3. Schrappe M, Reiter A, Zimmermannn M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALLBFM study group from 1981 to 1995. Leukemia. 2000;14:2205-2222.
4. Poplack D. Acute lymphoblastic leukemia. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 2nd ed. Philadelphia: Lippincott-PhilaRaven; 1993:431-481.
5. Gaynon PS, Steinherz PG, Bleyer WA, et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Children's Cancer Group Study CCG-106. J Clin Oncol. 1993;11:2234-2242.
6. Veerman AJP, Hahlen K, Van Leeuwen EF, et al. High cure rate with a moderately intensive treatment regimen in non-high risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol. 1996;14:911-918.
7. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Children's Cancer Group Phase III Trial. J Clin Oncol. 1993;11:527-537.
8. Buendia MTA, Terselich G, Lozano JM, et al. Acute lymphoblastic leukemia in children: nonrandomized comparison of conventional vs. intensive-chemotherapy at the National Cancer Institute of Colombia. Med Pediatr Oncol. 1997;28:108-116.
9. Pui CH, Crist WM, Look AT. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood. 1990;76:1449-1463.
10. Abromowitch M, Ochs J, Pui CH, et al. High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St Jude Total Therapy Study X. Med Pediatr Oncol. 1998;16:297-303.
11. Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N Engl J Med. 1986;314:471-477.
12. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Children's Cancer Group Report. J Clin Oncol. 1993;11:520-526.
13. Pullen J, Boyett J, Shuster J, et al. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol. 1993;11:839-849.
14. Gelber R, Sallan SE, Cohen H, et al. Central nervous system treatment in childhood acute lymphoblastic leukemia. Cancer. 1993;72:261-270.
15. Bennett JM, Catovski D, Daniel MT, et al. Proposals for the classification of the acute leukemias, French-American-British (FAB) Cooperative Group. Br J Hematol. 1976;33:451-458.
16. Williams DL, Harris A, Williams KJ, et al. A direct bone marrow chromosome technique for acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1984;13:239-246.
17. Jones B, Freeman AI, Shuster JJ, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphoblastic leukemia. Med Pediatr Oncol. 1991;19:269-275.
18. Balis FM, Lester CM, Chrousos GP, et al. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol. 1987;5:202-207.
19. Magrath I. Malignant non-Hodgkin's lymphomas in children. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 2nd ed. Philadelphia: Lippincott-PhilaRaven; 1993:537-575.
20. Relling MV, Fairclough D, Ayers D, et al. Patients characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol. 1994;12:1667-1672.
21. Wolfrom C, Hartman R, Fengler R, et al. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol. 1993;11:827-833.
22. Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event free survival for children with T-cell lymphoblastic lymphoma: a BFM Group Report. Blood. 2000;95:416-421.
23. The World Bank. The little data book 2006. WA: Communications Development Incorporated; 2006:65.
24. Gaynon PS, Lustig RH. The use of glucocorticoids in acute lymphoblastic leukaemia of childhood. J Pediatr Hematol Oncol. 1995;17:1-12.
25. Nachman J, Sather HN, Cherlow J, et al. Response of children with high risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. J Clin Oncol. 1998;16:920-930.
26. Conter V, Schrappe M, Arico M, et al. Role of cranial radiotherapy for children T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. J Clin Oncol. 1997;15: 2786-2791.
27. Conter V, Arico M, Valsecchi C, et al. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt- Munster-based intensive-chemotherapy. J Clin Oncol. 1995;13:2497-2502.
28. Steinherz PG. CNS-leukemia: problem of diagnosis, treatment, and outcome. J Clin Oncol. 1995;13:310-313.
29. Tubergen DG, Cullen JW, Boyett JM, et al. Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission: a Children's Cancer Group Study. J Clin Oncol. 1994;12:273-278.
30. Nachman JB, Sather HN, Sensel MG, et al. Augmented postinduction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663-1671.
31. Arico M, Valsecchi MG, Conter V, et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisonepoor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood. 2002;100:420-426.
32. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18-24.
33. Bonilla M, Moreno N, Neyesa M, et al. Acute lymphoblastic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador. J Pediatr Hematol Oncol. 2000;22:495-501.
34. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia. Cancer. 1997;80:1717-1726.
35. Gajjar A, Ribeiro R, Hancock M, et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood. 1995; 86:1292-1295.
36. Thyss A, Suciu S, Bertrand Y, et al. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 1997;15:1824-1830.
37. Locasciulli A, Alberti A, Rossetti F, et al. Acute and chronic hepatitis in childhood leukemia: a Multicentric Study from the Italian Pediatric Cooperative Group for Therapy of Acute Leukemia (AIL-AIEOP). Med Pediatr Oncol. 1985;13:203-206.
38. Buitrago B. Patologia geografica: historia natural de las hepatitis B y D en Colombia. Biomedica. 1991;11:5-26.
39. American Academy of Pediatrics. Hepatitis B. In: Pickering LK, ed. Red Book (Libro Rojo). Memoria del Comité de Enfermedades Infecciosas para 2003. 26a ed. Mexico: Intersistemas; 2004: 383-403.
40. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trial in childhood acute lymphoblastic leukemia: 1.983-1.995. Leukemia. 2000;14:2223-2233.
41. Maloney KW, Shuster JJ, Murphy S, et al. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group Studies from 1986-1994. Leukemia. 2000;14: 2276-2285.